Zymeworks Inc (ZYME) |
|
29.98 -0.31 (-1.02%)
|
08-13 16:00 |
|
Open: |
30.17 |
Pre. Close: |
30.29 |
|
High:
|
31.04 |
Low:
|
29.81 |
|
Volume:
|
494,220 |
Market Cap:
|
1,368M |
|
|
|
|
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and collaboration with Applied BioMath, LLC. Zymeworks Inc. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
31.128 - 31.3 |
31.3 - 31.44 |
|
Low:
|
29.284 - 29.525 |
29.525 - 29.721 |
|
Close:
|
29.626 - 29.983 |
29.983 - 30.273 |
|
Technical analysis |
as of: 2020-08-13 4:40:01 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 38.25 One year: 40.95 |
| Support: |
Support1: 29.00 Support2: 24.13 |
| Resistance: |
Resistance1: 32.75 Resistance2: 35.06 |
| Pivot: |
30.63 |
| Moving Average: |
MA(5): 30.45 MA(20): 30.87
MA(100): 35.15  MA(250): 35.87 |
| MACD: |
MACD(12,26): -0.94 Signal(9): -1.07 |
| Stochastic oscillator: |
%K(14,3): 33.24 %D(3): 39.64 |
| RSI: |
RSI(14): 40.24 |
| 52-week: |
High: 52.75 Low: 20.33 Change(%): 13.6 |
| Average Vol(K): |
3-Month: 42857 10-Days: 27710 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.ZYME has closed above bottom band by 28.9%. Bollinger Bands are 55.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to ZYME's normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Fri, 07 Aug 2020
Wall street estimates Earnings report Zymeworks (NYSE:ZYME) - Stock Market Daily
Thu, 06 Aug 2020
Benzinga's Top Upgrades, Downgrades For August 6, 2020 - Benzinga
Thu, 06 Aug 2020
Is a Surprise Coming for Zymeworks (ZYME) This Earnings Season? - Nasdaq
Wed, 05 Aug 2020
Zymeworks Inc. (ZYME) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Wed, 05 Aug 2020
Zymeworks Reports 2020 Second Quarter Financial Results - Business Wire
Fri, 31 Jul 2020
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: New York Stock Exchange |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
46 |
| Shares Float (M) |
36 |
|
% Held by Insiders
|
10.12 |
|
% Held by Institutions
|
60.11 |
|
Shares Short (K)
|
2,240 |
|
Shares Short P. Month (K)
|
1,170 |
Stock Financials |
|
EPS
|
-3.870 |
|
EPS Est This Year
|
-2.980 |
|
EPS Est Next Year
|
-2.540 |
|
Book Value (p.s.)
|
11.470 |
|
Profit Margin
|
|
|
Operating Margin
|
-664.31 |
|
Return on Assets (ttm)
|
-24.6 |
|
Return on Equity (ttm)
|
-47.1 |
|
Qtrly Rev. Growth
|
-30.7 |
|
Gross Profit (p.s.)
|
-1.896 |
|
Sales Per Share
|
0.569 |
|
EBITDA (p.s.)
|
-3.712 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-98 |
|
Levered Free Cash Flow (M)
|
-34 |
Stock Valuations |
|
PE Ratio
|
-7.75 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.61 |
|
Price to Sales
|
52.73 |
|
Price to Cash Flow
|
-13.93 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
